08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Celladon, Servier deal

Celladon granted Servier an exclusive option to license ex-U.S. rights to discover, develop and commercialize ATPase Ca++ transporting cardiac muscle slow twitch 2b ( ATP2A2b ; SERCA2b ) modulators for Type II diabetes and other...
08:00 , Mar 3, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Anika Therapeutics Inc. (NASDAQ:ANIK) rose $11.43 (33%) to $45.90 on Wednesday after saying FDA approved Monovisc to treat osteoarthritis of the knee. Monovisc is a single injection that delivers hyaluronic acid from a...
01:03 , Feb 25, 2014 |  BC Extra  |  Company News

Celladon gains on Servier option

Celladon Corp. (NASDAQ:CLDN) jumped as much as 94% on Monday before closing the day up $1.93 (26%) to $9.50 after granting Servier (Neuilly-sur-Seine, France) an exclusive option to license ex-U.S. rights to discover, develop and...
08:00 , Nov 11, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes ATPase Ca++ transporting cardiac muscle slow twitch 2b (ATP2A2b; SERCA2b) Studies in mice suggest that increasing SERCA2b levels could help treat diabetes. In...